keyword
MENU ▼
Read by QxMD icon Read
search

prostatic cancer

keyword
https://www.readbyqxmd.com/read/28449574/the-clinical-utilization-of-radiation-therapy-in-korea-between-2011-and-2015
#1
Young-Seok Seo, Mi-Sook Kim, Jin-Kyu Kang, Won-Il Jang, Hee Jin Kim, Chul Koo Cho, Hyung Jun Yoo, Eun Kyung Paik, Yu Jin Cha, Jae Sun Yoon
Purpose: The purpose of this study was to estimate the clinical utilization of radiation therapy (RT) in Korea between 2011 and 2015. Materials and Methods: We analyzed the claims data from the Health Insurance Review and Assessment Service (HIRA) to estimate the clinical utilization of RT. The source population consisted of all patients who had any of the International Classification of Diseases 10 (ICD-10) cancer diagnoses (C00-C97) and those with diagnostic codes D00-D48, who were also associated with at least one of the procedure codes related to RT...
April 25, 2017: Cancer Research and Treatment: Official Journal of Korean Cancer Association
https://www.readbyqxmd.com/read/28449236/discovery-of-lhrh-and-development-of-lhrh-analogs-for-prostate-cancer-treatment
#2
Andrew V Schally, Norman L Block, Ferenc G Rick
The discovery, isolation, elucidation of structure, synthesis, and initial testing of the neuropeptide hypothalamic luteinizing hormone-releasing hormone (LHRH), which regulates reproduction, is briefly described. The design, synthesis, and experimental and clinical testing of agonistic analogs of LHRH is extensively reviewed focusing on the development of new methods for the treatment of prostate cancer. Subsequent development of antagonistic analogs of LHRH is then faithfully recounted with special emphasis on therapy of prostate cancer and BPH...
April 27, 2017: Prostate
https://www.readbyqxmd.com/read/28449007/efficacy-of-stereotactic-body-radiotherapy-in-oligorecurrent-and-in-oligoprogressive-prostate-cancer-new-evidence-from-a-multicentric-study
#3
Luca Triggiani, Filippo Alongi, Michela Buglione, Beatrice Detti, Riccardo Santoni, Alessio Bruni, Ernesto Maranzano, Frank Lohr, Rolando D'Angelillo, Alessandro Magli, Alberto Bonetta, Rosario Mazzola, Nadia Pasinetti, Giulio Francolini, Gianluca Ingrosso, Fabio Trippa, Sergio Fersino, Paolo Borghetti, Paolo Ghirardelli, Stefano Maria Magrini
BACKGROUND: The aim of the present study is to evaluate the impact of metastases-directed stereotactic body radiotherapy in two groups of oligometastatic prostate cancer (PC) patients: oligorecurrent PC and oligoprogressive castration-resistant PC (oligo-CRPC). METHODS: Inclusion criteria of the present multicentre retrospective analysis were: (1) oligorecurrent PC, defined as the presence of 1-3 lesions (bone or nodes) detected with choline positron emission tomography or CT plus bone scan following biochemical recurrence; (2) oligo-CRPC, defined as metastases (bone or nodes) detected after a prostatic-specific antigen rise during androgen deprivation therapy (ADT)...
April 27, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28448495/dysregulation-of-inf2-mediated-mitochondrial-fission-in-spop-mutated-prostate-cancer
#4
Xiaofeng Jin, Jie Wang, Kun Gao, Pingzhao Zhang, Longfang Yao, Yan Tang, Lisha Tang, Jian Ma, Jiantao Xiao, Enceng Zhang, Jie Zhu, Bin Zhang, Shi-Min Zhao, Yao Li, Shancheng Ren, Haojie Huang, Long Yu, Chenji Wang
Next-generation sequencing of the exome and genome of prostate cancers has identified numerous genetic alternations. SPOP (Speckle-type POZ Protein) was one of the most frequently mutated genes in primary prostate cancer, suggesting SPOP is a potential driver of prostate cancer development and progression. However, how SPOP mutations contribute to prostate cancer pathogenesis remains poorly understood. SPOP acts as an adaptor protein of the CUL3-RBX1 E3 ubiquitin ligase complex that generally recruits substrates for ubiquitination and subsequent degradation...
April 27, 2017: PLoS Genetics
https://www.readbyqxmd.com/read/28448269/circulating-cell-free-micrornas-as-clinical-cancer-biomarkers
#5
REVIEW
Virginie Armand-Labit, Anne Pradines
MicroRNAs (miRNAs) are non-coding small RNAs that are master regulators of genic expression and consequently of many cellular processes. But their expression is often deregulated in human tumors leading to cancer development. Recently miRNAs were discovered in body fluids (serum, plasma and others) and their levels have often been reported to be altered in patients. Circulating miRNAs became one of the most promising biomarkers in oncology for early diagnosis, prognosis and therapeutic response prediction. Here we describe the origins and roles of miRNAs, and summarize the most recent studies focusing on their usefulness as cancer biomarkers in lung, breast, colon, prostate, ovary cancers and melanoma...
April 27, 2017: Biomolecular Concepts
https://www.readbyqxmd.com/read/28448241/prediction-of-breast-and-prostate-cancer-risks-in-male-brca1-and-brca2-mutation-carriers-using-polygenic-risk-scores
#6
Julie Lecarpentier, Valentina Silvestri, Karoline B Kuchenbaecker, Daniel Barrowdale, Joe Dennis, Lesley McGuffog, Penny Soucy, Goska Leslie, Piera Rizzolo, Anna Sara Navazio, Virginia Valentini, Veronica Zelli, Andrew Lee, Ali Amin Al Olama, Jonathan P Tyrer, Melissa Southey, Esther M John, Thomas A Conner, David E Goldgar, Saundra S Buys, Ramunas Janavicius, Linda Steele, Yuan Chun Ding, Susan L Neuhausen, Thomas V O Hansen, Ana Osorio, Jeffrey N Weitzel, Angela Toss, Veronica Medici, Laura Cortesi, Ines Zanna, Domenico Palli, Paolo Radice, Siranoush Manoukian, Bernard Peissel, Jacopo Azzollini, Alessandra Viel, Giulia Cini, Giuseppe Damante, Stefania Tommasi, Paolo Peterlongo, Florentia Fostira, Ute Hamann, D Gareth Evans, Alex Henderson, Carole Brewer, Diana Eccles, Jackie Cook, Kai-Ren Ong, Lisa Walker, Lucy E Side, Mary E Porteous, Rosemarie Davidson, Shirley Hodgson, Debra Frost, Julian Adlard, Louise Izatt, Ros Eeles, Steve Ellis, Marc Tischkowitz, Andrew K Godwin, Alfons Meindl, Andrea Gehrig, Bernd Dworniczak, Christian Sutter, Christoph Engel, Dieter Niederacher, Doris Steinemann, Eric Hahnen, Jan Hauke, Kerstin Rhiem, Karin Kast, Norbert Arnold, Nina Ditsch, Shan Wang-Gohrke, Barbara Wappenschmidt, Dorothea Wand, Christine Lasset, Dominique Stoppa-Lyonnet, Muriel Belotti, Francesca Damiola, Laure Barjhoux, Sylvie Mazoyer, Mattias Van Heetvelde, Bruce Poppe, Kim De Leeneer, Kathleen B M Claes, Miguel de la Hoya, Vanesa Garcia-Barberan, Trinidad Caldes, Pedro Perez Segura, Johanna I Kiiski, Kristiina Aittomäki, Sofia Khan, Heli Nevanlinna, Christi J van Asperen, Tibor Vaszko, Miklos Kasler, Edith Olah, Judith Balmaña, Sara Gutiérrez-Enríquez, Orland Diez, Alex Teulé, Angel Izquierdo, Esther Darder, Joan Brunet, Jesús Del Valle, Lidia Feliubadalo, Miquel Angel Pujana, Conxi Lazaro, Adalgeir Arason, Bjarni A Agnarsson, Oskar Th Johannsson, Rosa B Barkardottir, Elisa Alducci, Silvia Tognazzo, Marco Montagna, Manuel R Teixeira, Pedro Pinto, Amanda B Spurdle, Helene Holland, Jong Won Lee, Min Hyuk Lee, Jihyoun Lee, Sung-Won Kim, Eunyoung Kang, Zisun Kim, Priyanka Sharma, Timothy R Rebbeck, Joseph Vijai, Mark Robson, Anne Lincoln, Jacob Musinsky, Pragna Gaddam, Yen Y Tan, Andreas Berger, Christian F Singer, Jennifer T Loud, Mark H Greene, Anna Marie Mulligan, Gord Glendon, Irene L Andrulis, Amanda Ewart Toland, Leigha Senter, Anders Bojesen, Henriette Roed Nielsen, Anne-Bine Skytte, Lone Sunde, Uffe Birk Jensen, Inge Sokilde Pedersen, Lotte Krogh, Torben A Kruse, Maria A Caligo, Sook-Yee Yoon, Soo-Hwang Teo, Anna von Wachenfeldt, Dezheng Huo, Sarah M Nielsen, Olufunmilayo I Olopade, Katherine L Nathanson, Susan M Domchek, Christa Lorenchick, Rachel C Jankowitz, Ian Campbell, Paul James, Gillian Mitchell, Nick Orr, Sue Kyung Park, Mads Thomassen, Kenneth Offit, Fergus J Couch, Jacques Simard, Douglas F Easton, Georgia Chenevix-Trench, Rita K Schmutzler, Antonis C Antoniou, Laura Ottini
Purpose BRCA1/2 mutations increase the risk of breast and prostate cancer in men. Common genetic variants modify cancer risks for female carriers of BRCA1/2 mutations. We investigated-for the first time to our knowledge-associations of common genetic variants with breast and prostate cancer risks for male carriers of BRCA1/ 2 mutations and implications for cancer risk prediction. Materials and Methods We genotyped 1,802 male carriers of BRCA1/2 mutations from the Consortium of Investigators of Modifiers of BRCA1/2 by using the custom Illumina OncoArray...
April 27, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28447913/testosterone-replacement-therapy-and-risk-of-favorable-and-aggressive-prostate-cancer
#7
Stacy Loeb, Yasin Folkvaljon, Jan-Erik Damber, Joseph Alukal, Mats Lambe, Pär Stattin
Purpose The association between exposure to testosterone replacement therapy (TRT) and prostate cancer risk is controversial. The objective was to examine this association through nationwide, population-based registry data. Methods We performed a nested case-control study in the National Prostate Cancer Register of Sweden, which includes all 38,570 prostate cancer cases diagnosed from 2009 to 2012, and 192,838 age-matched men free of prostate cancer. Multivariable conditional logistic regression was used to examine associations between TRT and risk of prostate cancer (overall, favorable, and aggressive)...
May 1, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28447434/the-influence-of-different-muscle-mass-measurements-on-the-diagnosis-of-cancer-cachexia
#8
Susanne Blauwhoff-Buskermolen, Jacqueline A E Langius, Annemarie Becker, Henk M W Verheul, Marian A E de van der Schueren
BACKGROUND: Progressive loss of muscle mass is a major characteristic of cancer cachexia. Consensus definitions for cachexia provide different options to measure muscle mass. This study describes the effect of different methods to determine muscle mass on the diagnosis of cancer cachexia. In addition, the association of cachexia with other features of cachexia, quality of life, and survival was explored. METHODS: Prior to chemotherapy, cachexia was assessed by weight loss, body mass index, and muscle mass measurements, the latter by mid-upper arm muscle area (MUAMA), computed tomography (CT) scans, and bio-electrical impedance analysis (BIA)...
April 26, 2017: Journal of Cachexia, Sarcopenia and Muscle
https://www.readbyqxmd.com/read/28447314/inhibition-of-the-insulin-like-growth-factor-1-receptor-potentiates-acute-effects-of-castration-in-a-rat-model-for-prostate-cancer-growth-in-bone
#9
Annika Nordstrand, Sofia Halin Bergström, Elin Thysell, Erik Bovinder-Ylitalo, Ulf H Lerner, Anders Widmark, Anders Bergh, Pernilla Wikström
Prostate cancer (PCa) patients with bone metastases are primarily treated with androgen deprivation therapy (ADT). Less pronounced ADT effects are seen in metastases than in primary tumors. To test if acute effects of ADT was enhanced by concurrent inhibition of pro-survival insulin-like growth factor 1 (IGF-1), rats were inoculated with Dunning R3327-G tumor cells into the tibial bone marrow cavity and established tumors were treated with castration in combination with IGF-1 receptor (IGF-1R) inhibitor NVP-AEW541, or by each treatment alone...
April 26, 2017: Clinical & Experimental Metastasis
https://www.readbyqxmd.com/read/28446934/endoscopic-extraperitoneal-radical-prostatectomy-after-radical-resection-of-pt1-pt2-rectal-cancer-a-report-of-thirty-cases
#10
Zhuo Liu, Dechuan Li, Yinbo Chen
INTRODUCTION: Endoscopic extraperitoneal radical prostatectomy (EERPE) has gained popularity for the treatment of localized prostate cancer. However, prior complex lower abdominal or pelvic surgery can complicate subsequent EERPE. To date, there have been few reports on patients who underwent EERPE after radical resection of pT1-pT2 rectal cancer. AIM: To present our experience with EERPE in patients after radical resection of pT1-pT2 rectal carcinoma and introduce a simple and effective way to create an extraperitoneal working space...
2017: Wideochirurgia i Inne Techniki Mało Inwazyjne, Videosurgery and Other Miniinvasive Techniques
https://www.readbyqxmd.com/read/28446545/a-pooled-analysis-of-15-prospective-cohort-studies-on-the-association-between-fruit-vegetable-and-mature-bean-consumption-and-risk-of-prostate-cancer
#11
Joshua Petimar, Kathryn M Wilson, Kana Wu, Molin Wang, Demetrius Albanes, Piet A van den Brandt, Michael B Cook, Graham G Giles, Edward L Giovannucci, Gary G Goodman, Phyllis J Goodman, Niclas Håkansson, Kathy Helzlsouer, Timothy J Key, Laurence N Kolonel, Linda M Liao, Satu Männistö, Marjorie L McCullough, Roger L Milne, Marian L Neuhouser, Yikyung Park, Elizabeth A Platz, Elio Riboli, Norie Sawada, Jeannette M Schenk, Shoichiro Tsugane, Bas Verhage, Ying Wang, Lynne R Wilkens, Alicja Wolk, Regina G Ziegler, Stephanie A Smith-Warner
BACKGROUND: Relationships between fruit, vegetable, and mature bean consumption and prostate cancer risk are unclear. METHODS: We examined associations between fruit and vegetable groups, specific fruits and vegetables, and mature bean consumption and prostate cancer risk overall, by stage and grade, and for prostate cancer mortality in a pooled analysis of 15 prospective cohorts, including 52,680 total cases and 3,205 prostate cancer deaths among 842,149 men. Diet was measured by a food frequency questionnaire or similar instrument at baseline...
April 26, 2017: Cancer Epidemiology, Biomarkers & Prevention
https://www.readbyqxmd.com/read/28446540/human-prostate-luminal-cell-differentiation-requires-notch3-induction-by-p38-mapk-and-myc
#12
Sander B Frank, Penny L Berger, Mats Ljungman, Cindy K Miranti
Many pathways dysregulated in prostate cancer are also involved in epithelial differentiation. To better understand prostate tumor initiation, we sought to investigate specific genes and mechanisms required for normal basal to luminal cell differentiation. Utilizing human prostate basal epithelial cells and an in vitro differentiation model, we tested the hypothesis that p38-MAPK regulation of NOTCH3, via MYC, is required for luminal differentiation. Inhibition (SB202190, BIRB796) or knockdown of p38α and/or p38δ prevented proper differentiation...
April 26, 2017: Journal of Cell Science
https://www.readbyqxmd.com/read/28446506/analytic-pre-analytic-and-clinical-validation-of-p53-immunohistochemistry-for-detection-of-tp53-missense-mutation-in-prostate-cancer
#13
Liana Guedes, Fawaz Almutairi, Michael C Haffner, Gaurav Rajoria, Zach Liu, Szczepan Klimek, Roberto Zoino, Kasra Yousefi, Rajni Sharma, Angelo M De Marzo, George Netto, William B Isaacs, Ashley E Ross, Edward M Schaeffer, Tamara L Lotan
PURPOSE:TP53 missense mutations may help to identify prostate cancer (PCa) with lethal potential. Here, we pre-analytically, analytically and clinically validated a robust immunohistochemistry (IHC) assay to detect subclonal and focal TP53 missense mutations in PCa. <p>EXPERIMENTAL DESIGN: The p53 IHC assay was performed in a CLIA-accredited laboratory on the Ventana Benchmark immunostaining system. p53 protein nuclear accumulation was defined as any p53 nuclear labeling in >10% of tumor cells. 54 formalin fixed paraffin embedded (FFPE) cell lines from the NCI-60 panel and 103 FFPE PCa tissues (88 primary adenocarcinomas, 15 metastases) with known TP53 mutation status were studied...
April 26, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28446230/label-retention-and-stem-cell-marker-expression-in-the-developing-and-adult-prostate-identifies-basal-and-luminal-epithelial-stem-cell-subpopulations
#14
Jens Adam Ceder, Tilly Wilhelmina Aalders, Jack Antonius Schalken
BACKGROUND: Prostate cancer is the second most frequent cancer among males worldwide, and most patients with metastatic disease eventually develop therapy-resistant disease. Recent research has suggested the existence of cancer stem-like cells, and that such cells are behind the therapy resistance and progression. METHODS: Here, we have taken advantage of the relatively quiescent nature of stem cells to identify the slow-cycling label-retaining stem cell (LRC) populations of the prostate gland...
April 26, 2017: Stem Cell Research & Therapy
https://www.readbyqxmd.com/read/28446159/the-quality-of-medicaid-and-medicare-data-obtained-from-cms-and-its-contractors-implications-for-pharmacoepidemiology
#15
Charles E Leonard, Colleen M Brensinger, Young Hee Nam, Warren B Bilker, Geralyn M Barosso, Margaret J Mangaali, Sean Hennessy
BACKGROUND: Administrative claims of United States Centers for Medicare and Medicaid Services (CMS) beneficiaries have long been used in non-experimental research. While CMS performs in-house checks of these claims, little is known of their quality for conducting pharmacoepidemiologic research. We performed exploratory analyses of the quality of Medicaid and Medicare data obtained from CMS and its contractors. METHODS: Our study population consisted of Medicaid beneficiaries (with and without dual coverage by Medicare) from California, Florida, New York, Ohio, and Pennsylvania...
April 26, 2017: BMC Health Services Research
https://www.readbyqxmd.com/read/28446009/applications-of-microfluidic-devices-for-urology
#16
REVIEW
Se Jik Han, Hun-Kuk Park, Kyung Sook Kim
Microfluidics is considered an important technology that is suitable for numerous biomedical applications, including cancer diagnosis, metastasis, drug delivery, and tissue engineering. Although microfluidics is still considered to be a new approach in urological research, several pioneering studies have been reported in recent years. In this paper, we reviewed urological research works using microfluidic devices. Microfluidic devices were used for the detection of prostate and bladder cancer and the characterization of cancer microenvironments...
April 2017: International Neurourology Journal
https://www.readbyqxmd.com/read/28445989/tmprss2-erg-gene-fusion-variants-induce-tgf-%C3%AE-signaling-and-epithelial-to-mesenchymal-transition-in-human-prostate-cancer-cells
#17
Leonie Ratz, Mark Laible, Lukasz A Kacprzyk, Stephanie M Wittig-Blaich, Yanis Tolstov, Stefan Duensing, Peter Altevogt, Sabine M Klauck, Holger Sültmann
TMPRSS2:ERG (T/E) gene fusions are present in approximately 50% of all prostate cancer (PCa) cases. The expression of fusion mRNAs from distinct T/E variants is associated with clinicopathological parameters, while the underlying molecular processes remain unclear. We characterized the molecular mechanisms and functional implications caused by doxycycline (Dox)-inducible overexpression of the frequent T/E III and VI fusion variants in LNCaP cells. Induction of T/E expression resulted in increased cellular migratory and invasive potential, and reduced proliferation and accumulation in G1 phase...
April 11, 2017: Oncotarget
https://www.readbyqxmd.com/read/28445975/functional-fgfr4-gly388arg-polymorphism-contributes-to-cancer-susceptibility-evidence-from-meta-analysis
#18
Si-Wei Xiong, Jianqun Ma, Fen Feng, Wen Fu, Shan-Rong Shu, Tianjiao Ma, Caixia Wu, Guo-Chang Liu, Jinhong Zhu
Fibroblast growth factor receptor 4 (FGFR4) is a member of receptor tyrosine kinase family. A functional Gly388Arg (rs351855 G>A) polymorphism in FGFR4 gene causes a glycine-to-arginine change at codon 388 within the transmembrane domain of the receptor. Although the FGFR4 rs351855 G>A polymorphism has been implicated in cancer development, its association with cancer risk remains controversial. Here, we have systematically analyzed the association between the rs351855 G>A polymorphism and cancer risk by performing a meta-analysis of 27 studies consisting of 8,682 cases and 9,731 controls...
April 11, 2017: Oncotarget
https://www.readbyqxmd.com/read/28445962/psma-homing-dsrna-chimeric-protein-vector-kills-prostate-cancer-cells-and-activates-anti-tumor-bystander-responses
#19
Yael Langut, Nufar Edinger, Efrat Flashner-Abramson, Naomi Melamed-Book, Mario Lebendiker, Yael Levi-Kalisman, Shoshana Klein, Alexander Levitzki
The treatment of metastatic androgen-resistant prostate cancer remains a challenge. We describe a protein vector that selectively delivers synthetic dsRNA, polyinosinic/polycytidylic acid (polyIC), to prostate tumors by targeting prostate specific membrane antigen (PSMA), which is overexpressed on the surface of prostate cancer cells.The chimeric protein is built from the double stranded RNA (dsRNA) binding domain of PKR tethered to a single chain anti-PSMA antibody. When complexed with polyIC, the chimera demonstrates selective and efficient killing of prostate cancer cells...
April 11, 2017: Oncotarget
https://www.readbyqxmd.com/read/28445813/microfluidic-integrated-patterned-ito-immunosensor-for-rapid-detection-of-prostate-specific-membrane-antigen-biomarker-in-prostate-cancer
#20
Rajesh Seenivasan, Chandra K Singh, Jay W Warrick, Nihal Ahmad, Sundaram Gunasekaran
An optically transparent patterned indium tin oxide (ITO) three-electrode sensor integrated with a microfluidic channel was designed for label-free immunosensing of prostate-specific membrane antigen (PSMA), a prostate cancer (PCa) biomarker, expressed on prostate tissue and circulating tumor cells but also found in serum. The sensor relies on cysteamine capped gold nanoparticles (N-AuNPs) covalently linked with anti-PSMA antibody (Ab) for target specificity. A polydimethylsiloxane (PDMS) microfluidic channel is used to efficiently and reproducibly introduce sample containing soluble proteins/cells to the sensor...
April 11, 2017: Biosensors & Bioelectronics
keyword
keyword
82207
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"